IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity

被引：0
|
作者：
Khurshed, Mohammed
Aarnoudse, Niels
Hulsbos, Renske
Hira, Vashendriya V. V.
van Laarhoven, Hanneke W. M.
Wilmink, Johanna W.
Molenaar, Remco J.
van Noorden, Cornelis J.
机构：
来源：
FASEB JOURNAL | 2019年 / 33卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
250.8
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses
    Cheng, Wen
    Ren, Xiufang
    Zhang, Chuanbao
    Cai, Jinquan
    Han, Sheng
    Wu, Anhua
    MOLECULAR NEUROBIOLOGY, 2017, 54 (08) : 5996 - 6005
  • [32] IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation
    Landberg, Niklas
    Kohnke, Thomas
    Feng, Yang
    Nakauchi, Yusuke
    Fan, Amy C.
    Linde, Miles H.
    Karigane, Daiki
    Lim, Kelly
    Sinha, Rahul
    Malcovati, Luca
    Thomas, Daniel
    Majeti, Ravindra
    BLOOD CANCER DISCOVERY, 2024, 5 (02): : 114 - 131
  • [33] PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF AG-120, A POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF IDH1-MUTANT ADVANCED HEMATOLOGIC MALIGNANCIES
    Fan, B.
    Chen, Y.
    Wang, F.
    Yen, K.
    Utley, L.
    Prahl, M.
    Colby, K.
    Straley, K.
    Bowden, C.
    Biller, S.
    Agresta, S.
    Yang, H.
    HAEMATOLOGICA, 2015, 100 : 218 - 218
  • [34] PARACRINE IMPAIRMENT OF ANTITUMOR T CELL IMMUNITY BY IDH1-MUTANT GLIOMAS
    Bunse, L.
    Bunse, T.
    Pusch, S.
    Sahm, F.
    Sanghvi, K.
    Berghoff, A.
    Steadman, M.
    Niemeyer, B.
    Wick, W.
    Platten, M.
    NEURO-ONCOLOGY, 2016, 18 : 4 - 5
  • [35] DNMT3A co-mutation in an IDH1-mutant glioblastoma
    Fomchenko, Elena, I
    Erson-Omay, E. Zeynep
    Zhao, Amy
    Bindra, Ranjit S.
    Huttner, Anita
    Fulbright, Robert K.
    Moliterno, Jennifer
    COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2019, 5 (04):
  • [36] Altered Oxidative Phosphorylation Confers Vulnerability on IDH1-Mutant Leukemia Cells: Is This Therapeutically Tractable?
    Steensma, David P.
    BLOOD CANCER DISCOVERY, 2024, 5 (02): : 83 - 85
  • [37] Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
    Victor Ruiz-Rodado
    Adrian Lita
    Tyrone Dowdy
    Orieta Celiku
    Alejandra Cavazos Saldana
    Herui Wang
    Chun Zhang Yang
    Raj Chari
    Aiguo Li
    Wei Zhang
    Hua Song
    Meili Zhang
    Susie Ahn
    Dionne Davis
    Xiang Chen
    Zhengping Zhuang
    Christel Herold-Mende
    Kylie J. Walters
    Mark R. Gilbert
    Mioara Larion
    Cancer & Metabolism, 8
  • [38] Longitudinal Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-Mutant Advanced Hematologic Malignancies
    Fan, Bin
    Le, Kha
    Manyak, Erika
    Liu, Hua
    Prahl, Malia
    Bowden, Chris J.
    Biller, Scott
    Agresta, Sam
    Yang, Hua
    BLOOD, 2015, 126 (23)
  • [39] ZEB1 expression is increased in IDH1-mutant lower-grade gliomas
    Nesvick, Cody L.
    Zhang, Chao
    Edwards, Nancy A.
    Montgomery, Blake K.
    Lee, Michaela
    Yang, Chunzhang
    Wang, Herui
    Zhu, Dongwang
    Heiss, John D.
    Merrill, Marsha J.
    Ray-Chaudhury, Abhik
    Zhuang, Zhengping
    JOURNAL OF NEURO-ONCOLOGY, 2016, 130 (01) : 111 - 122
  • [40] Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
    Lowery, Maeve A.
    Burris, Howard A., III
    Janku, Filip
    Shroff, Rachna T.
    Cleary, James M.
    Azad, Nilofer S.
    Goyal, Lipika
    Maher, Elizabeth A.
    Gore, Lia
    Hollebecque, Antoine
    Beeram, Muralidhar
    Trent, Jonathan C.
    Jiang, Liewen
    Fan, Bin
    Aguado-Fraile, Elia
    Choe, Sung
    Bin Wu
    Gliser, Camelia
    Agresta, Samuel, V
    Pandya, Shuchi S.
    Zhu, Andrew X.
    Abou-Alfa, Ghassan K.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (09): : 711 - 720
12345